Rationale: This case illustrates the therapeutic potential of the Ayurvedic mode of management in a chronic type II diabetes mellitus (T2DM) patient with metabolic syndrome (MetS), where conventional treatment is unable to sustain the desired effects. It also tries to observe clinical reporting of any adverse drug interactions between Ayurveda and allopathy systems of medication.
INTRODUCTION
Diabetes mellitus is a chronic, heterogeneous, and life-threatening disease. The prevalence of diabetes in 2014 was 382 million and is estimated to scale up to an alarming 592 million by 2035 by the International Diabetes Federation. Nearly 80% of people with diabetes are in the low-and middle-income countries. 1 Moreover, greater than 60% of the world diabetes population will be in Asia. India, Nepal, and China have shown an increasing prevalence of diabetes even among the rural population. 2 The escalating rate of obesity is a major causative factor for the increasing prevalence of T2DM. 3 Metabolic syndrome is considered as the new epidemic of the 21st century. It is a major and escalating public health and clinical challenge worldwide in the wake of urbanization, surplus energy intake, increasing obesity, and sedentary life habits. 4 The MetS confers a 5-fold increase in the risk of T2DM and 2-fold risk of developing cardiovascular disease. 5 Further, patients
with MetS are at 2-to 4-fold increased risk of stroke, a 3-to 4-fold increased risk of myocardial infarction, and 2-fold risk of dying from such an event compared with those without the syndrome regardless of a previous history of cardiovascular events. 6, 7 This case illustrates the therapeutic potential of the Ayurvedic mode of management in a chronic T2DM patient with MetS where conventional treatment was unable to sustain the desired effects. It also tries to observe clinical reporting of any adverse drug interactions between Ayurvedic and allopathic medications. Further, it emphasizes on the need to understand a patient based on Ayurvedic fundamental principles in order to decipher the unique "samprapti" (pathogenesis of disease) of the disease before planning the intervention.
CASE REpORT
A 55-year-old Indian male presented in May 2017 at the outpatient department of AYUSH Wellness Clinic with complaints of poor glycemic control, despite taking oral hypoglycemic medication, hypertriglyceridemia, and chronic constipation with fullness of stomach, gas, and abdominal bloating. Patient is diabetic for the past 10 years, and the constipation history is more than 20 years. Also, the patient presented history of hypertension for the past 2½ years and hypertriglyceridemia for the past 1 year. No history of any type of addiction was present. His family history was positive for T2DM.
When first diagnosed in 2007, the patient was put on Glibenclamide 5 mg, an antidiabetic drug in a class of medication known as sulfonylureas. With increasing blood sugar levels in July 2014, the medication was changed to Metformin (a biguanide oral hypoglycemic drug) and Sitagliptin (an oral hypogylcemic drug of a class that inhibits the enzyme dipeptidyl peptidase-4 inhibitor) in a combination of 500 mg/50 mg twice daily. In January 2015, when diagnosed with hypertension, he was put on Ramipril 2.5 mg once daily. In December 2015, the dose of Metformin and Sitagliptin combination had been increased to 1 gm/50 mg twice daily with addition of Glimepiride 1 mg, an antidiabetic drug in a class of medications known as sulfonylureas, once daily as the fasting blood sugar (FBS) was 155 mg/dL and postprandial (PP) was 271 mg/dL. In December 2015, the dose of Ramipril (angiotensin-converting enzyme inhibitor) had been increased to 5 mg once daily as the blood pressure was not being controlled. At the time of consultation in May 2017, the patient was on Metformin and Sitagliptin 1 gm/50 mg twice daily and Ramipril 5 mg once daily. In March 2016, hypertriglyceridemia and borderline hypercholesterolemia was detected and he was advised to control diet and do regular exercise. The drug compliance was good, and diet and exercise were irregular. With the oral hypoglycemic medications, the abdominal complaints worsened and so he had stopped Glimepiride 1 mg for the past 6 months. Patient was not on any lipid-lowering medication.
DIAGNOSTIC EVALUATION AND ASSESSMENT
The present case is diagnosed as T2DM based on history and as per American Diabetes Association A1c criteria. The patient was further diagnosed with MetS based on the Harmonized criteria (2009): A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute (NHLBI); American heart association (AHA); World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
Any three of the following traits in the same individual meet the criteria for the MetS. • High-density lipoprotein (HDL) cholesterol 40 mg/dL or lower in men and 50 mg/dL or lower in women.
• Blood pressure of 130/85 or more.
• Fasting blood glucose of 100 mg/dL or above.
At the time of consultation, the blood reports showed FBS: 83 mg/dL, PP: 218 mg/dL, glycated hemoglobin (HbA1c): 7.9%, urea: 19 mg/dL, creatinine: 0.7 mg/dL, total cholesterol: 182 mg/dL, triglycerides: 275 mg/dL, very lowdensity lipoprotein (VLDL): 55 mg/dL, HDL: 46 mg/dL, and low-density lipoprotein (LDL): 81 mg/dL. Patient's blood pressure was 130/85 mm Hg, weight 75 kg, height 171 cm, and waist circumference 102 cm. The body mass index was 26, suggesting being overweight and waist circumference shows abdominal obesity.
Clinically, the patient was complaining of chronic constipation, fullness of stomach, gas, and bloating of abdomen. Based on the clinical observations, history, and as per the above-mentioned diagnostic criteria, the patient was diagnosed as T2DM with MetS and chronic constipation and on Ayurvedic parlance as Avaranajanya madhumeha (~diabetes due to occlusion)/Sthula pramehi (~diabetic with obesity) with Vibanda (constipation) based on the etiology and signs and symptoms as per classical texts 8 ( Tables 1 and 2 ).
TREATMENT AND OUTCOME
At first appointment on May 30, 2017, the patient presented with poor glycemic control, hypertriglyceridemia, constipation, fullness of stomach, gas, and bloating. He was put on the following Ayurvedic medicines: Phalatrikadi Kwath, 9 M Liv Tablet, Lavanabhaskar Churna, 10 Arogyavardini vati, 11 Eranda taila 12 (Table 1) , and was asked to continue oral hypoglycemic (Metformin and Sitagliptin 1 gm/50 mg BD) and antihypertensive (Ramipril 5 mg OD) medication as usual. Further, he was given dietary and lifestyle advice ( Table 1) . The second appointment on June 14, 2017 included a review of laboratory results and an updated symptom assessment. The patient was feeling much better, totally relieved of the GIT complaints, and his laboratory parameters also showed improvement, better regulation of blood sugar, and total control of hypertriglycerides. Blood pressure was normal, but no reduction in weight was observed. After two weeks of medication, there was no adverse drug interactions reported ( Table 1) .
The third appointment on June 20, 2017 included an updated symptom assessment. Patient was complaining again of constipation and, hence, supplemented with Eranda taila (Table 1) . The fourth appointment on July 20, 2017 included a review of laboratory results and an updated symptom assessment. Laboratory parameters showed marked improvement and sustained the improvement noted of earlier readings of the third appointment. Patient was better relief of with constipation and gas trouble. Blood pressure was normal, no reduction in weight was observed, and a 2 cm reduction in waist circumference were noted. Patient was advised to stop M. Liv tablet and Arogyavardini vati and continue the remaining medications. Again, no adverse drug interactions were reported and the liver function tests and kidney functions tests were within normal limits (Table 1) .
DISCUSSION
Through its contribution to cardiovascular disease, stroke, and mortality, the increasing prevalence of T2DM along with MetS is a huge health challenge and an economic burden to the world.
Ayurveda, the eternal system of medicine, has documented various clinical conditions and their management is based on its fundamental principles. Diabetes mellitus and MetS can be understood and managed based on the principles of "Prameha" (~umbrella term for various metabolic disorders involving pathogenesis of urinary system) especially Sthula pramehi/Avaranajanya Madhumeha. 13 Acharya Charaka has mentioned that a physician need to examine the three important factors viz., Samuthana vishesha (the specific causative factors for disease manifestation), Adhistana vishesha (the site of manifestation of disease), and Vikara prakriti (the nature of disease pathway) for successful management of the patient even when the physician is unable to make the diagnosis or name the disease as per the clinical condition of the patient. Due to intake of predominantly Abhishandi ahara (food that blocks the channels of circulation) and Vidahikara ahara (food that causes burning sensation), the Kapha and Pitta doshas (regulatory functional factors of the body) and Medo and Raktha dhatu dusti (derangement of major structural components of the body) occur, leading to its primary manifestation in Yakruth (liver), which is the moola sthana (prime/major site or location) of Rakthavaha srotas and Adhistana (~abode) of Bhutagni (digestive/metabolic factors pertaining to five elements), leading to fatty infiltration of liver. Further, the metabolic conversion of Vijateeya (heterogeneous) to Sajateeya dravyas (homogeneous) will get affected resulting in insulin resistance, dyslipidemia, and hypertension. This condition of MetS, if further Santarpana nidana (etiology related to overnourishment) is followed, can lead to T2DM, which as per Ayurvedic principles can be understood as resulting in the manifestation of Prameha, specifically leading to a condition of Sthula pramehi/Avaranajanya Madhumeha as it is resulting out of Santapana nidana.
As per Ayurveda, each and every individual is unique, and so his development of illness will also be unique as well as specific to the individual. Hence, it is important to decipher the Visesha samprapti (specific pathogenesis of disease) in a patient based on Ayurvedic principles before administering the intervention.
In the present case, for the past 20 years, the patient was constantly suffering with gastric complaints, especially constipation. Due to a sedentary lifestyle and unhealthy food habits with a family history of diabetes, he developed T2DM 10 years back, which eventually resulted in MetS. Due to the chronic vitiation of Apana vata (Table 3) :
Along with the above medication, diet and lifestyle modifications followed by the patient were also to be considered for encouraging results. No significant reduction in weight was observed, but the patient was feeling more active and healthy.
Due to lack of proper documentation, there is a serious doubt regarding the allopathic and Ayurvedic drug interactions. This case documents that there are no adverse drug interactions.
LIMITATIONS
Chronic conditions and their treatments are usually multifactorial, complicating the evaluation of cause-andeffect relationship between symptoms and treatment. The results cannot be generalized as the present case stresses the need for individualized approach.
CONCLUSION
Chronic T2DM with MetS is at risk of cardiovascular disease and stroke, and better management will reduce the risks. This case demonstrates the need to stick to the classical therapeutic principles of Ayurveda and apply them rationally to get the best possible outcomes, and it also throws light on the model of integrated approach. The integrated effect of the therapeutics as well as the patient's choices and involvement contributed to the present outcome.
pATIENT pERSpECTIVE "I feel totally relieved with the GIT complaints which I was suffering since many years. With better regulation of blood sugar I feel more active, energetic and overall quality of life got much improved."
INFORMED CONSENT
An informed written consent was obtained from the patient for reporting this case. 
